Amgen: Lymphoma trials

The registry lists 23 Lymphoma studies with Amgen as lead sponsor. 0 are open to participants now and 12 have results posted.

Phase 1 9Phase 2 15Phase 3 1No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular LymphomaTerminatedNCT03571828Phase 1Results posted
• Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)CompletedNCT03340766Phase 1Results posted
• Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT)TerminatedNCT03298412Phase 2Results posted
• Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell LymphomaCompletedNCT03023878Phase 2Results posted
• A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's LymphomaCompletedNCT02961881Phase 1Results posted
• Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHLCompletedNCT02910063Phase 2/3Results posted
• Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac DiseaseCompletedNCT02633020Phase 2Results posted
• Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)CompletedNCT01741792Phase 2Results posted
• Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum CalciumCompletedNCT00896454Phase 2Results posted
• Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or LymphomaCompletedNCT00531284Phase 1/2Results posted
• A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With LymphomaCompletedNCT00283439Phase 1/2Results posted
• Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHLCompletedNCT00274742Phase 1Results posted
• AMG 319 Lymphoid Malignancy FIHCompletedNCT01300026Phase 1
• IMPACT Non Hodgkins Lymphoma (NHL) StudyCompletedNCT00903812
• Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or VorinostatCompletedNCT00791011Phase 1
• AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin LymphomaCompletedNCT00562380Phase 1
• Treatment for Subjects With Non-Hodgkin's LymphomaCompletedNCT00117897Phase 2
• A Study of Peripheral Blood Progenitor Cell (PBPC) Mobilisation by Chemotherapy With Pegfilgrastim or Filgrastim in Subjects With Non-Hodgkin's LymphomaCompletedNCT00117455Phase 2
• Pegfilgrastim Administered on the Same Day as Chemotherapy in Non-Hodgkin's LymphomaCompletedNCT00115193Phase 2
• Pegfilgrastim PBPC Mobilization StudyCompletedNCT00066092Phase 2
• Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma (Low-Grade)CompletedNCT00044902Phase 2
• Study of T900607-Sodium in Previously Treated Patients With Non-Hodgkin's Lymphoma.TerminatedNCT00043459Phase 2
• Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's LymphomaStatus unknownNCT00005959Phase 2